COVID-19 in persons with haematological cancers
COVID-19 in persons with haematological cancers
复制标题
DOI：
10.1038/s41375-020-0836-7
复制
发表时间：
2020-04-24
期刊：
影响因子：
11.4
通讯作者：
Gale, Robert Peter
中科院分区：
文献类型：
--
作者：
He, Wenjuan;Chen, Lei;Gale, Robert Peter
感染SARS-CoV-2（冠状病毒传染病-19（COVID-19）的原因）已导致全球超过850，000例的大流行病，并且还在增加。几项研究报告了COVID-19在主要健康人群中的结果。也有一些关于COVID-19在主要患有实体癌的人中的数据，但这些人是否具有相同的结果存在争议。我们在中国武汉的两个中心进行了一项队列研究，纳入了128名住院的血液系统癌症受试者，其中13名（10%）发展为COVID-19。我们还研究了226名医疗保健提供者，其中16人患上了COVID-19，11人住院治疗。将协变量与115名非COVID-19的血液系统癌症受试者和11名患有COVID-19的住院医疗保健提供者进行比较。发生或未发生COVID-19的血液系统癌症受试者之间的基线协变量无显著差异。血液系统癌症住院受试者的COVID-19病例率为10%（95%置信区间[CI]，6，17%），而医疗保健提供者的病例率为7%（4，12%; P = 0.322）。然而，与因COVID-19住院的医疗保健提供者相比，13名血液系统癌症受试者的COVID-19更严重，死亡人数更多。病死率分别为62%（32，85%）和0（0，32%; P = 0.002）。与正常医疗保健提供者相比，血液系统癌症住院患者的COVID-19发病率相似，但疾病更严重，病死率更高。由于我们无法确定血液癌症住院患者中COVID-19的特定风险因素，我们建议加强监测和可能的保护性隔离。
Infection with SARS-CoV-2, the cause of coronavirus infectious disease-19 (COVID-19), has caused a pandemic with >850,000 cases worldwide and increasing. Several studies report outcomes of COVID-19 in predominately well persons. There are also some data on COVID-19 in persons with predominately solid cancer but controversy whether these persons have the same outcomes. We conducted a cohort study at two centres in Wuhan, China, of 128 hospitalised subjects with haematological cancers, 13 (10%) of whom developed COVID-19. We also studied 226 health care providers, 16 of whom developed COVID-19 and 11 of whom were hospitalised. Co-variates were compared with the 115 subjects with haematological cancers without COVID-19 and with 11 hospitalised health care providers with COVID-19. There were no significant differences in baseline co-variates between subjects with haematological cancers developing or not developing COVID-19. Case rates for COVID-19 in hospitalised subjects with haematological cancers was 10% (95% Confidence Interval [CI], 6, 17%) compared with 7% (4, 12%; P = 0.322) in health care providers. However, the 13 subjects with haematological cancers had more severe COVID-19 and more deaths compared with hospitalised health care providers with COVID-19. Case fatality rates were 62% (32, 85%) and 0 (0, 32%; P = 0.002). Hospitalised persons with haematological cancers have a similar case rate of COVID-19 compared with normal health care providers but have more severe disease and a higher case fatality rate. Because we were unable to identify specific risk factors for COVID-19 in hospitalised persons with haematological cancers, we suggest increased surveillance and possible protective isolation.